|
CONTENTS
|
|
|
|
Detection,
diagnosis and evaluation
Etiology
and pathogenesis
Integrative
medicine
Overall
management
Prognosis
and outcome
Prostate-specific
antigen
Quality
of life
Treatment
|
|
|
|
|
DETECTION,
DIAGNOSIS AND EVALUATION
|
|
|
|
Bratan F, Melodelima C,
Souchon R, Dinh AH, Mège-Lechevallier F, Crouzet S,
Colombel M, Gelet A, Rouvière O.
How
Accurate Is Multiparametric MR Imaging in Evaluation of
Prostate Cancer Volume?
Radiology. 2014 Nov 21:140524. [Epub ahead of print]
Abstract
| Related
citations
|
|
|
Wang J, Kudchadker R, Choi
S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh
TJ, Hoffman K, Mahmood U, Kuban DA.
Local
recurrence map to guide target volume delineation after radical
prostatectomy.
Pract Radiat Oncol. 2014;4(6):e239-46. doi:
10.1016/j.prro.2014.02.007. Epub 2014 Apr 16.
Abstract
| Related
citations
|
|
ETIOLOGY
AND PATHOGENESIS
|
|
|
|
Stoletov K, Bond D, Hebron
K, Raha S, Zijlstra A, Lewis JD.
Metastasis
as a therapeutic target in prostate cancer: a conceptual
framework.
Am J Clin Exp Urol. 2014 Apr;2(1):45-56.
Abstract
| Full
text |
Related
citations
|
|
INTEGRATIVE
MEDICINE
|
|
|
|
Alumkal JJ, Slottke R,
Schwartzman J, Cherala G, Munar M, Graff JN, Beer TM, Ryan CW,
Koop DR, Gibbs A, Gao L, Flamiatos JF, Tucker E, Kleinschmidt
R, Mori M.
A
phase II study of sulforaphane-rich broccoli sprout extracts in
men with recurrent prostate cancer.
Invest New Drugs. 2014 Nov 29. [Epub ahead of print]
Abstract
| Related
citations
|
|
|
Küllenberg de Gaudry D,
Massing U.
[Importance
of long chain omega-3 fatty acids in prostate cancer].
Urologe A. 2014 Nov;53(11):1620-4. doi:
10.1007/s00120-014-3612-3.
Abstract
| Related
citations
|
|
OVERALL
MANAGEMENT
|
|
|
|
Aggarwal RR, Small
EJ.
Small-cell/neuroendocrine
prostate cancer: a growing threat?
Oncology (Williston Park). 2014 Oct;28(10). pii: 201920.
Abstract
| Full
text |
Related
citations
|
|
|
Aparicio A, Tzelepi
V.
Neuroendocrine
(Small-Cell) Carcinomas: Why They Teach Us Essential Lessons
About Prostate Cancer.
Oncology (Williston Park). 2014 Oct 15;28(10). pii: 201919.
Abstract
| Full
text |
Related
citations
|
|
PROGNOSIS
AND OUTCOME
|
|
|
|
Lee JJ, Thomas IC, Nolley R,
Ferrari M, Brooks JD, Leppert JT.
Biologic
differences between peripheral and transition zone prostate
cancer.
Prostate. 2014 Oct 18. doi: 10.1002/pros.22903. [Epub ahead
of print]
Abstract
| Related
citations
|
|
|
Patrikidou A, Loriot Y,
Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier
B, Fizazi K.
Who
dies from prostate cancer?
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):348-52. doi:
10.1038/pcan.2014.35. Epub 2014 Oct 14.
Abstract
| Related
citations
|
|
|
Biochemical
recurrence
|
|
|
Cancer-specific
mortality
|
|
|
Salvage
androgen deprivation therapy following biochemical failure
post-salvage radiation therapy
|
|
|
Foster CC, Jackson WC,
Foster BC, Johnson SB, Feng FY, Hamstra DA.
Less
advanced disease at initiation of salvage androgen deprivation
therapy is associated with decreased mortality following
biochemical failure post-salvage radiation therapy.
Radiat Oncol. 2014 Nov 26;9(1):245. [Epub ahead of print]
Abstract
| Full
text |
Related
citations
|
|
|
Positive
surgical margins and cancer-specific mortality
|
|
|
Retèl VP, Bouchardy
C, Usel M, Neyroud-Caspar I, Schmidlin F, Wirth G, Iselin C,
Miralbell R, Rapiti E.
Determinants
and effects of positive surgical margins after prostatectomy on
prostate cancer mortality: a population-based study.
BMC Urol. 2014 Nov 5;14:86. doi: 10.1186/1471-2490-14-86.
Abstract
| Full
text |
Related
citations
|
|
|
Positive
surgical margins
|
|
|
Watkins JM, Laszewski M,
Watkins PL, Dufan TA, Adducci C.
Margin
involvement at prostatectomy for clinically localized prostate
cancer: Does a low-risk group exist?
Pract Radiat Oncol. 2015 Jan-Feb;5(1):e31-6. doi:
10.1016/j.prro.2014.04.005. Epub 2014 Jun 2.
Abstract
| Related
citations
|
|
PROSTATE-SPECIFIC
ANTIGEN
|
|
|
|
Kabarriti R, Ohri N, Hannan
R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R,
Kalnicki S, Guha C, Garg MK.
Prostate-specific
antigen decline during salvage radiation therapy following
prostatectomy is associated with reduced biochemical failure.
Pract Radiat Oncol. 2014;4(6):409-14. doi:
10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.
Abstract
| Related
citations
|
|
|
Servoll E, Sæter T,
Vlatkovic L, Nesland JM, Waaler G, Axcrona K.
Prostate-specific
antigen doubling time subsequent to radical prostatectomy is a
predictor of outcome following salvage external beam radiation
therapy: A single-centre experience.
Scand J Urol. 2014 Nov 27:1-6. [Epub ahead of print]
Abstract
| Full
text |
Related
citations
|
|
|
Suzman DL, Zhou XC, Zahurak
ML, Lin J, Antonarakis ES.
Change
in PSA velocity is a predictor of overall survival in men with
biochemically-recurrent prostate cancer treated with
nonhormonal agents: combined analysis of four phase-2 trials.
Prostate Cancer Prostatic Dis. 2014 Nov 11. doi:
10.1038/pcan.2014.44. [Epub ahead of print]
Abstract
| Related
citations
|
|
QUALITY
OF LIFE
|
|
|
|
Shen MJ, Nelson CJ, Peters
E, Slovin SF, Hall SJ, Hall M, Herrera PC, Leventhal EA,
Leventhal H, Diefenbach MA.
Decision-making
Processes among Prostate Cancer Survivors with Rising PSA
Levels: Results from a Qualitative Analysis.
Med Decis Making. 2014 Nov 10. pii: 0272989X14558424. [Epub
ahead of print]
Abstract
| Related
citations
|
|
TREATMENT
|
|
|
|
James ND, Spears MR, Clarke
NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin
PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar
MK, Ritchie AW, Russell JM, Strebel RT, Thalmann GN, Mason MD,
Sydes MR.
Survival
with Newly Diagnosed Metastatic Prostate Cancer in the
"Docetaxel Era": Data from 917 Patients in the
Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Eur Urol. 2014 Oct 6. pii: S0302-2838(14)00969-5. doi:
10.1016/j.eururo.2014.09.032. [Epub ahead of print]
Abstract
| Full
text |
Related
citations
|
|
|
Castration-resistant
prostate cancer
|
|
|
Satoh T, Uemura H, Tanabe K,
Nishiyama T, Terai A, Yokomizo A, Nakatani T, Imanaka K, Ozono
S, Akaza H.
A
phase 2 study of abiraterone acetate in japanese men with
metastatic castration-resistant prostate cancer who had
received docetaxel-based chemotherapy.
Jpn J Clin Oncol. 2014 Dec;44(12):1206-15. doi:
10.1093/jjco/hyu148. Epub 2014 Oct 1.
Abstract
| Full
text |
Related
citations
|
|
|
Wen SM, Quan CY, Jiang N,
Shang ZQ, Niu YJ.
What
is the next generation therapeutic strategy for
castration-resistant prostate cancer.
Asian J Androl. 2014 Nov 18. doi: 10.4103/1008-682X.143311.
[Epub ahead of print]
Abstract
| Full
text |
Related
citations
|
|
|
Decision
making
|
|
|
Su MZ, Kneebone AB, Woo
HH.
Adjuvant
versus salvage radiotherapy following radical prostatectomy: do
the AUA/ASTRO guidelines have all the answers?
Expert Rev Anticancer Ther. 2014 Nov;14(11):1265-70. doi:
10.1586/14737140.2014.972381.
Abstract
| Full
text |
Related
citations
|
|
|
|
|